GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sichuan Kelun Pharmaceutical Co Ltd (SZSE:002422) » Definitions » Return-on-Tangible-Asset

Sichuan Kelun Pharmaceutical Co (SZSE:002422) Return-on-Tangible-Asset : 11.50% (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sichuan Kelun Pharmaceutical Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sichuan Kelun Pharmaceutical Co's annualized Net Income for the quarter that ended in Mar. 2024 was ¥4,105 Mil. Sichuan Kelun Pharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2024 was ¥35,682 Mil. Therefore, Sichuan Kelun Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 11.50%.

The historical rank and industry rank for Sichuan Kelun Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:002422' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.71   Med: 3.46   Max: 7.67
Current: 7.67

During the past 13 years, Sichuan Kelun Pharmaceutical Co's highest Return-on-Tangible-Asset was 7.67%. The lowest was 2.71%. And the median was 3.46%.

SZSE:002422's Return-on-Tangible-Asset is ranked better than
74.33% of 1083 companies
in the Drug Manufacturers industry
Industry Median: 1.61 vs SZSE:002422: 7.67

Sichuan Kelun Pharmaceutical Co Return-on-Tangible-Asset Historical Data

The historical data trend for Sichuan Kelun Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun Pharmaceutical Co Return-on-Tangible-Asset Chart

Sichuan Kelun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.26 2.75 3.65 5.43 7.24

Sichuan Kelun Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.67 6.91 6.60 5.66 11.50

Competitive Comparison of Sichuan Kelun Pharmaceutical Co's Return-on-Tangible-Asset

For the Drug Manufacturers - General subindustry, Sichuan Kelun Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Kelun Pharmaceutical Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sichuan Kelun Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun Pharmaceutical Co's Return-on-Tangible-Asset falls into.



Sichuan Kelun Pharmaceutical Co Return-on-Tangible-Asset Calculation

Sichuan Kelun Pharmaceutical Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=2456.112/( (32748.119+35059.363)/ 2 )
=2456.112/33903.741
=7.24 %

Sichuan Kelun Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=4104.752/( (35059.363+36304.453)/ 2 )
=4104.752/35681.908
=11.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Sichuan Kelun Pharmaceutical Co  (SZSE:002422) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Sichuan Kelun Pharmaceutical Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun Pharmaceutical Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Kelun Pharmaceutical Co (SZSE:002422) Business Description

Traded in Other Exchanges
N/A
Address
No.36 West Baihua Road, Qingyang District, Chengdu, CHN, 610071
Sichuan Kelun Pharmaceutical Co Ltd is a China-based Pharmaceutical company mainly focused on the production and sales of injection products, including products for glucose injection and sodium chloride injection. It manufactures and sells high-volume injections (infusions), small-volume injections (water needles), sterile powder injections (containing powdered and freeze-dried powder). Its products include tablets, capsules, capsules, granules, oral liquids, peritoneal dialysis fluids, raw material medicines, medical packaging materials, medical instruments, and antibiotic intermediates.
Executives
Lai De Gui Executives
Feng Hao Directors, executives
Liu Si Chuan Directors, executives
Wang Jing Yi Directors, executives
Wan Yang Yu Executives
Ge Jun You Executives
Wu Zhong Hua Executives
Wan Peng Supervisors
Tan Hong Bo Executives
Liu Ge Xin Director
Huang Xin Securities Affairs Representative
Ge Tao Executives
Pan Hui Directors, executives
Zhou Xiao Dong Executives
Zheng Chang Yan Supervisors

Sichuan Kelun Pharmaceutical Co (SZSE:002422) Headlines

No Headlines